The Scottish Medicines Consortium has
today published its acceptance of ixekizumab (Taltz) as a treatment for psoriatic
arthritis in Scotland.
Ixekizumab is accepted to treat
psoriatic arthritis in the following circumstances:
Taltz binds to a cytokine (chemical
messenger) called interleukin-17A (IL-17A), which is involved in the body’s
inflammatory and immune responses. By binding to IL-17A, Taltz inhibits its
action (ie. stops it from working as it usually does). This means Taltz
interrupts the inflammatory cycle of psoriasis and psoriatic arthritis, which
can lead to the improvement in symptoms for many people who take it.
Like other biologic treatments for psoriasis and
psoriatic arthritis, Taltz is taken via injection. It is an immunosuppressive
treatment – meaning it reduces the activity of part of the immune system
thought to be involved in psoriasis. You can read more information on the
action of Taltz, as well as its dosing regime and possible side effects
by downloading our information sheet.